Ajugol's upregulation of TFEB-mediated autophagy alleviates endoplasmic reticulum stress in chondrocytes and retards osteoarthritis progression in a mouse model

Screening of ESR2-targeted anti-postmenopausal osteoporosis chemistry from Rehmanniae Radix Preparata based on affinity ultrafiltration with UPLC-QE-Orbitrap-MS

Rehmanniae Radix Preparata, a processed form of the traditional Chinese medicinal plant Rehmannia glutinosa Libosch, has long been valued for its medicinal properties and use as a food. It is notably effective in treating postmenopausal osteoporosis. This study utilized C18 to separate and purify different concentrations of its eluent streams. MC3T3-E1 cells were utilized to identify the optimal ESR2 activity fraction from various concentrations of Rehmanniae Radix Preparata, using osteoprotegerin (OPG) as an indicator. A single-target affinity ultrafiltration method was created, combining ESR2 affinity ultrafiltration with liquid chromatography-mass spectrometry (LC-MS). Molecular docking validated the interaction mechanism between small molecule ligands and ESR2 protein. These ligands were then tested in MC3T3-E1 cells to assess survival rate, OPG content, and alkaline phosphatase (ALP) activity, an osteogenic differentiation marker. The study showed that Radix Rehmanniae Praeparata effectively combats PMOP, and the combined method of single-target-affinity ultrafiltration-LC-MS with molecular docking offers a robust approach for identifying its anti-PMOP compounds.

Guilu Erxian glue reduces endoplasmic reticulum stress-mediated apoptosis and restores the balance of extracellular matrix synthesis and degradation in chondrocytes by inhibiting the ATF6/GRP78/CHOP signaling pathway

Knee Osteoarthritis (KOA) is characterized by phenotypic alterations, apoptosis, and the breakdown of the extracellular matrix (ECM) in the superficial articular cartilage cells. The inflammatory response activates the Endoplasmic Reticulum Stress (ERS) signaling pathway, which plays a critical role in the pathophysiology and progression of KOA. Chondrocytes stimulated by thapsigargin(TG)exhibit heightened ERS and significantly increase the expression of ERS-associated proteins. Key mediators of ERS-induced apoptosis include X-box-binding protein 1(XBP1), elevated levels of the protein transport protein Sec61 subunit (SEC61), and C/EBP homologous protein (CHOP). While the precise mechanism of action of Guilu Erxian Glue (GEG), a medication commonly used in the clinical treatment of KOA, remains to be fully elucidated, our research has shown that GEG mitigates the imbalance between ECM synthesis and degradation, as well as chondrocyte apoptosis resulting from ERS. This effect is likely achieved through the suppression of the Activating Transcription Factor 6 (ATF6)/Glucose-Regulatory Protein 78 (GRP78)/CHOP signaling pathway. In summary,our research results indicate that GEG can activate the ATF6/GRP78/CHOP signaling pathway to restore endoplasmic reticulum (ER) homeostasis in chondrocytes, thereby reducing chondrocyte apoptosis and ultimately promoting the balance between ECM synthesis and degradation.

Changes in Rehmanniae Radix processing and their impact on ovarian hypofunction: potential mechanisms of action

Objective

This study evaluates the research developments concerning Rehmanniae Radix in ovarian hypofunction diseases. It explores the processing methods of Rehmanniae Radix, the variations in its compounds before and after processing, the mechanism of Rehmanniae Radix and its active compounds in improving ovarian function, and the advancements in clinical applications of traditional Chinese medicine (TCM) compound that include Rehmanniae Radix.

Methods

Comprehensive literature search was conducted using databases such as China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, National Science and Technology Library, the Pharmacopoeia of the People's Republic of China, Pubmed, and the Web of Science Database. The search utilized the following Medical Subject Headings (MeSH) and keywords: "Rehmanniae Radix," "Drying Rehmannia Root," "Rehmannia glutinosa," "Rehmanniae Radix Praeparata," "Traditional Chinese Medicine Processing," "Pharmacological Effects," "Ovarian Aging," "Diminished ovarian reserve," "Premature ovarian insufficiency," "Premature Ovarian Failure," "Ovarian hypofunction diseases".

Results

The ancient Chinese medical books document various processing techniques for Rehmanniae Radix. Contemporary research has identified changes in its compounds processing and the resultant diverse therapeutic effects. When processed into Rehmanniae Radix Praeparata, it is noted for its ability to invigorate the kidney. TCM compound containing Rehmanniae Radix is frequently used to treat ovarian hypofunction diseases, demonstrating significant clinical effectiveness. The key changes in its compounds processing include cyclic dilute ether terpene glycosides, phenylethanol glycosides, sugars, and 5-hydroxymethylfurfural. Its pharmacological action is primarily linked to the improvement of granulosa cell proliferation, antioxidative and anti-aging properties, and modulation of the immune and inflammatory microenvironment. Furthermore, Rehmanniae Radix also offers therapeutic benefits for cardiovascular and cerebrovascular diseases, osteoporosis and cognitive dysfunction caused by low estrogen levels. Thereby Rehmanniae Radix mitigates both the short-term and long-term health risks associated with ovarian hypofunction diseases.

Conclusion

Processed Rehmanniae Radix has shown potential to improve ovarian function, and its compound prescriptions have a definite effect on ovarian dysfunction diseases. Therefore Rehmanniae Radix was garnering interest for both basic and clinical research, with promising application prospects as a future therapeutic agent for ovarian hypofunction diseases. However, further studies on its toxicology and the design of standardized clinical trials are necessary to fully establish its efficacy and safety.

WITHDRAWN: The dysregulated autophagy in osteoarthritis: Revisiting molecular profile

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.